Pleco Therapeutics secures €17.3 million in Series A funding

Pleco Therapeutics is a cancer therapeutics developer offering preclinical development programs for cancer treatment, with current preclinical development programs focused on developing treatments for acute myeloid leukemia (AML) and small cell lung cancer (SCLC). Pleco Therapeutics BV announced the completion of a €17.3 million Series A financing. These financings include EUR 3.6 million in new equity pledged by Oost NL and selected private investors, EUR 5 million in government funding from Enterprise Netherlands (RVO), and EUR 8.7 million in equity and R&D project financing announced by Hyloris Pharmaceuticals SA at the end of 2021 .

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment